Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 344

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 344
---
 as cash outflows from operating activities in the consolidated statements of cash flows. 

2024 Form 10-K   |  82

Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2024 are shown in the table below:Basis of fair value measurement(in millions)Book value Approximate fair valuesQuoted prices in active markets for identical assets (Level 1)Significant other observable inputs (Level 2)Significant unobservable inputs (Level 3)LiabilitiesCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges$6,797 $6,767 $6,620 $147 $— Long-term debt and finance lease obligations, excluding fair value hedges and financing liability60,243 55,836 53,441 2,395 — Total liabilities$67,040 $62,603 $60,061 $2,542 $— The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2023 are shown in the table below: Basis of fair value measurement(in millions)Book value Approximate fair valuesQuoted prices in active markets for identical assets (Level 1)Significant other observable inputs (Level 2)Significant unobservable inputs (Level 3)LiabilitiesCurrent portion of long-term debt and finance lease obligations, excluding fair value hedges$7,191 $7,069 $6,862 $207 $— Long-term debt and finance lease obligations, excluding fair value hedges52,460 49,541 48,983 558 — Total liabilities$59,651 $56,610 $55,845 $765 $— AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $169 million as of December 31, 2024 and $159 million as of December 31, 2023. No significant cumulative upward or downward adjustments have been recorded for these investments as of December 31, 2024.Concentrations of RiskOf